CDT Equity announces 1-for-8 reverse stock split effective Oct 10

NAPLES, Fla. and CAMBRIDGE, United Kingdom - CDT Equity Inc. (NASDAQ:CDT) announced that its board of directors has approved a 1-for-8 reverse stock split of the company’s common stock, set to take effect on October 10, 2025, at 5:00 pm Eastern Time. The announcement comes as the company’s stock has declined nearly 99% year-to-date, currently trading at $0.74 with a market capitalization of just $2.26 million.

The company’s shares are expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on October 13, 2025, under the existing ticker symbol CDT but with a new CUSIP number (20678X403).

Following the reverse split, every eight shares of issued and outstanding common stock will be combined into one share, reducing the total number of outstanding shares to approximately 1,352,448. The par value will remain unchanged at $0.0001 per share.

The company’s board of directors received stockholder approval for future reverse stock splits at a Special Meeting held on May 5, 2025, which granted them authority to determine the exact split ratios. According to the announcement, directors expect the reverse split will increase the amount of funds the company might be able to raise to execute its strategy.

Proportional adjustments will be made to equity awards, convertible securities, and warrants, including their exercise prices. No fractional shares will be issued, with stockholders entitled to fractional shares receiving proportional cash payments instead.

Registered stockholders holding shares electronically in book-entry form will not need to take action to receive post-split shares. Those holding shares in brokerage accounts will have their positions automatically adjusted according to their brokers’ processes.

CDT Equity describes itself as a data-driven biopharmaceutical development company focused on identifying and advancing therapeutic assets through scientific innovation and strategic partnerships. The company reported a significant loss with earnings per share of -$52.4 over the last twelve months. InvestingPro subscribers can access 11 additional key insights about CDT’s financial position and market performance, helping investors make more informed decisions about this volatile biotech stock.

This information is based on a press release statement from the company.

In other recent news, CDT Equity Inc. announced a strategic acquisition of 8.65 Bitcoin for $1 million, aiming to bolster its financial position and enhance balance sheet resilience. This acquisition is part of CDT’s treasury reserve strategy, marking a significant move into digital assets. Additionally, CDT Equity disclosed that its unaudited financial statements for the quarter ending March 31, 2025, should no longer be relied upon due to a necessary restatement. The company, in consultation with its advisors and CBIZ CPAs P.C., found that $0.4 million in milestone payments to Sarborg Limited were misclassified as research and development expenses. These payments should have been recorded as an acquired diagnostic asset according to ASC 730 accounting standards. These developments reflect CDT Equity’s ongoing efforts to navigate financial reporting complexities while strategically investing in digital assets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.